 |
Investor Relations |
Current SEC Filings
| Form 10 KSB 2006 Form 10 KSB 2007 Form 10 K 2008 . |
Form 10 Q First Quarter 2009 Form 10 Q Second Quarter 2009 Form 10 Q Third Quarter 2009 Form 10 Q Fourth Quarter 2009 |
News
02 - 23 - 10: Vitro Appoints Prominent Denver Investment Banker to its Board of Directors
02-16-10: Vitro Co-sponsors Keystone Stem Cell Symposium
12-30-09: Vitro Raises Capital from Previous Investors
12-2-09: Vitro Develops Novel Reprogrammed Human Stem Cells and Files Patent
11-10-09: Vitro to Expand Manufacturing Capacity & Report Increased Product Sales for 2009
10-6-09: Research Reveals Unique Properties of Vitro’s Fluorescent Stem Cells
9-10-09: Vitro’s Cancer Stem Cell Therapy Complements New Hedge Hog Drugs
9-1-09: Vitro Builds Its Product and Technology Base for Cancer Stem Cell Therapy
8-11-09: Vitro Announces New Stem Cell Product to Support Clinical Trials Expanding Vitro’s Pipeline
6-9-09: Vitro Receives Adult Stem Cell Patent from the United States Patent and Trademark Office
5-19-09: Vitro Launches Products to Support Stem Cell Research and Drug Development
4-1-09: Vitro Introduces “Tools for Stem Cell and Drug Development™”
2-17-09: Experienced Cancer Researcher Joins Vitro’s Scientific Advisory Board
1-28-09: Vitro Receives Notice of Allowance for Adult Stem Cell Patent
from the United States Patent and Trademark Office
1-13-09: Vitro Announces Application of its Stem Cell Technology
to Cancer Research & Treatment - Files New Patent Application
7-30-08: Vitro Receives Approval for Preclinical Diabetes Study Protocol
7-9-08: Vitro Opens New Manufacturing Facility
6-17-08: Biopharmaceutical Scientist Joins Vitro’s Board
Transfer Agent:
Securities Transfer Corporation
2591 Dallas Parkway
Suite 102
Frisco, TX 75034
Phone: (469) 633-0101
FAX: (469) 633-0088
Website: www.stctransfer.com
Chart + Quote
Historical SEC Filings
Note: If either of these two charts do not function correctly please disable the pop-up blocker in your browser.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained within this website and subsequent oral statements made by and on behalf of the Company may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2008 under the caption, “Risk Factors” and subsequent SEC filings. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information,